Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Active not recruiting 3Suspended 1

Sponsor Class

NIH 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 1Lymphoid 1Gynecologic 1Genitourinary 1

Conditions

Carcinoma, Renal Cell 10Melanoma 9Neoplasm Metastasis 4Clear-cell metastatic renal cell carcinoma 4Carcinoma, Non-Small-Cell Lung 4Prostatic Neoplasms 3Myelodysplastic Syndromes 3Leukemia, Myeloid, Acute 3Carcinoma, Transitional Cell 3Carcinoma, Basal Cell 3Urogenital Neoplasms 2Urinary Bladder Neoplasms 2Urethral Neoplasms 2Thyroid Neoplasms 2Sarcoma 2Penile Neoplasms 2Ovarian Neoplasms 2Nasopharyngeal Carcinoma 2Lung Neoplasms 2Histiocytoma, Malignant Fibrous 2Glioblastoma 2Carcinoma, Merkel Cell 2Carcinoma, Endometrioid 2Brain Neoplasms 2Adenocarcinoma of Lung 2Vulvar Neoplasms 1Uveal Melanoma 1Ureteral Neoplasms 1Urachal adenocarcinoma 1Triple Negative Breast Neoplasms 1

Interventions

Specimen Handling 43pembrolizumab 42Biopsy 36Magnetic Resonance Spectroscopy 34Paclitaxel 21Carboplatin 21Gemcitabine 20Nivolumab 19Irinotecan 17Radiosurgery 15Cisplatin 13Taxes 11Pemetrexed 11Ipilimumab 11Fluorouracil 11Cetuximab 11trastuzumab deruxtecan 10olaparib 10Leucovorin 10130-nm albumin-bound paclitaxel 10abemaciclib 9Oxaliplatin 9Cyclophosphamide 9Capecitabine 9Bevacizumab 9palbociclib 8durvalumab 8Fulvestrant 8X-Rays 7Trastuzumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Neoplasm Metastasis × CTLA-4 Antigen × 90 days × Clear all
NCT04388852 2026-05-20

DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
65 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Prostatic Neoplasms

NCT03502733 2026-05-13

Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma

National Cancer Institute (NCI)

Phase 1 Active not recruiting
64 enrolled
Lymphoid

Lymphoma, Neoplasm Metastasis

NCT04317105 2026-05-13

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
54 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT04840589 2026-05-13

Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

National Cancer Institute (NCI)

Phase 1 Suspended
66 enrolled
Gynecologic

Neoplasm Metastasis, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡